Table 4.
Lipid-lowering treatment of the included patients in CNSR-III at 3-month, 6-month, 12-month follow-up (n=15 166)
| Treatment | Patients with statins, N (%) | ||||
| Hospitalisation | Discharge | 3 months | 6 months | 12 months | |
| Atorvastatin | 10 527 (69.4) | 9851 (65.0) | 8656 (57.1) | 8228 (54.3) | 7470 (49.3) |
| <40 mg | 7442 (70.7) | 8770 (89.0) | 8284 (95.7) | 7963 (96.8) | 7269 (97.4) |
| ≥40 mg | 3083 (29.3) | 1081 (11.0) | 372 (4.3) | 265 (3.2) | 198 (2.7) |
| Rosuvastatin | 3546 (23.4) | 3395 (22.4) | 2903 (19.1) | 2779 (18.3) | 2489 (16.4) |
| <20 mg | 2876 (81.2) | 2983 (87.9) | 2650 (91.4) | 2536 (91.3) | 2313 (93.0) |
| ≥20 mg | 668 (18.9) | 412 (12.1) | 250 (8.6) | 242 (8.7) | 176 (7.1) |
| Simvastatin | 272 (1.8) | 239 (1.6) | 390 (2.6) | 411 (2.7) | 444 (2.9) |
| Pravastatin | 166 (1.1) | 165 (1.1) | 137 (0.9) | 128 (0.8) | 100 (0.7) |
| Lovastatin | 25 (0.2) | 24 (0.2) | 33 (0.2) | 33 (0.2) | 30 (0.2) |
| Fluvastatin | 54 (0.4) | 53 (0.4) | 52 (0.3) | 43 (0.3) | 47 (0.3) |
| Pravastatin | 61 (0.4) | 78 (0.5) | 70 (0.5) | 64 (0.4) | 61 (0.4) |
CNSR-III, Third China National Stroke Registry.